Latest Biotech News

Merck & Co. announced a multiyear cost-reduction program aiming to save $3 billion annually by the end of 2027. The initiative will redirect resources from mature products to newer launches and...

Following FDA investigations into safety concerns, Sarepta Therapeutics received clearance to recommence shipments of its gene therapy Elevidys for ambulatory Duchenne muscular dystrophy patients....

GeneDx has upgraded its 2025 revenue guidance following robust second-quarter results, driven by a 49% year-over-year revenue increase. The genetic diagnostics firm saw whole-exome and...

GlaxoSmithKline has entered into a wide-ranging collaboration with Jiangsu Hengrui Pharmaceuticals valued at up to $12.5 billion, which includes an upfront payment of $500 million. The deal grants...

Minneapolis-based Celcuity announced positive topline results from its phase III Viktoria-1 trial evaluating gedatolisib combined with endocrine therapies in advanced HR+, HER2-, PIK3CA wild-type...

The GEN ’s “The State of CRISPR & Genome Editing” virtual summit, broadcast June 11, 2025, featured talks from leading researchers covering novel genome editing innovations. Highlights include...

Multiple reports detail AI's growing role in biotech. NIH researchers unveiled GeneAgent, an AI agent reducing errors in gene-set analysis via database verification. Stanford scientists developed...

Novo Nordisk revised its 2025 sales growth projection downward to 8%-14%, from an earlier 13%-21% estimate, citing increasing competition from compounded versions of its obesity drug Wegovy and...

Apellis Pharmaceuticals secured FDA approval for a supplemental new drug application expanding the use of its complement C3 inhibitor pegcetacoplan (Empaveli) to treat complement 3 glomerulopathy...

Merck & Co. revealed a sweeping initiative to cut costs by $3 billion annually by 2027, reallocating resources from mature products towards new drugs and experimental medicines. The effort aims to...

Novo Nordisk lowered its full-year sales forecast for 2025 to 8-14% growth, down from the earlier 13-21% estimate, citing ongoing challenges from cheaper knockoff versions of its obesity drug...

The FDA reversed a recent decision and authorized Sarepta Therapeutics to resume shipping its gene therapy Elevidys to ambulatory patients with Duchenne muscular dystrophy after concluding a...

Minneapolis-based Celcuity reported positive topline results from its phase III Viktoria-1 trial evaluating gedatolisib-based combinations for hormone receptor-positive, HER2-negative breast...

GlaxoSmithKline finalized a multi-billion dollar licensing agreement with Jiangsu Hengrui Pharmaceuticals granting rights to the potential best-in-class phosphodiesterase inhibitor HRS-9821 for...

European radiopharmaceutical company Artbio Therapeutics secured $132 million in Series B funding to advance its prostate cancer radioligand program into phase 2 clinical trials and expand its...

Sanofi CEO Paul Hudson stressed at Davos the value of AI in drug development decisions, highlighting that AI agents provide dispassionate recommendations without career bias. The company uses AI...

NeoGenomics reported a 10% revenue increase for the second quarter driven by clinical testing growth but slashed full-year revenue and earnings forecasts following delays and challenges in...

The NIH unveiled GeneAgent, an artificial intelligence system that mitigates hallucination errors in gene function prediction by autonomously cross-verifying outputs against curated biological...

GeneDx reported a 49% increase in second-quarter revenues to $102.7 million, surpassing Wall Street estimates and marking its fourth consecutive profitable quarter. The growth was primarily driven...

Sarepta Therapeutics has recommenced shipments of its gene therapy Elevidys® to ambulatory patients with Duchenne muscular dystrophy following a brief FDA-mandated pause. The reversal comes after...